AI assistant
NEOGENOMICS INC — Director's Dealing 2020
Feb 28, 2020
32227_dirs_2020-02-28_c2228073-898c-4f09-b877-5cfdf73b741b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2020-02-19
Reporting Person: Pedulla Denise E (General Counsel)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 41076 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock | $7.85 | 2020-12-08 | Common Stock (15000.0) | Direct | |
| Common Stock | $7.52 | 2022-04-28 | Common Stock (25000.0) | Direct | |
| Common Stock | $8.03 | 2023-02-26 | Common Stock (48334.0) | Direct | |
| Common Stock | $19.6 | 2024-03-01 | Common Stock (17496.0) | Direct |
Footnotes
F1: On December 8, 2015, Ms. Pedulla was granted an option to purchase 60,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.
F2: On April 28, 2017, Ms. Pedulla was granted an option to purchase 75,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
F3: On January 26, 2018, Ms. Pedulla was granted an option to purchase 72,500 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
F4: On March 1, 2019, Ms. Pedulla was granted an option to purchase 17,496 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.